157 related articles for article (PubMed ID: 36877775)
21. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
22. Whole-tumor histogram analysis of synthetic magnetic resonance imaging predicts isocitrate dehydrogenase mutation status in gliomas.
Ge X; Gan T; Yang Z; Liu G; Hu W; Ma W; Bai Y; Xiong Y; Li M; Zhao J; Zhou L; Li J; Li D; Wang X; Zhang J
Quant Imaging Med Surg; 2024 Mar; 14(3):2225-2239. PubMed ID: 38545061
[TBL] [Abstract][Full Text] [Related]
23. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
[TBL] [Abstract][Full Text] [Related]
24. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
26. Increased
Koyasu S; Shimizu Y; Morinibu A; Saga T; Nakamoto Y; Togashi K; Harada H
J Neurooncol; 2019 Dec; 145(3):441-447. PubMed ID: 31667733
[TBL] [Abstract][Full Text] [Related]
27. Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas.
Lu J; Li X; Li H
Magn Reson Imaging; 2021 Nov; 83():189-195. PubMed ID: 34506909
[TBL] [Abstract][Full Text] [Related]
28. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
29. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
30. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
[TBL] [Abstract][Full Text] [Related]
31. Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients.
Yan JL; van der Hoorn A; Larkin TJ; Boonzaier NR; Matys T; Price SJ
J Neurosurg; 2017 Jan; 126(1):234-241. PubMed ID: 27058207
[TBL] [Abstract][Full Text] [Related]
32. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
[TBL] [Abstract][Full Text] [Related]
33. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
[TBL] [Abstract][Full Text] [Related]
34. Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.
Hata N; Hatae R; Yoshimoto K; Murata H; Kuga D; Akagi Y; Sangatsuda Y; Suzuki SO; Iwaki T; Mizoguchi M; Iihara K
Neuropathology; 2017 Jun; 37(3):200-206. PubMed ID: 28116838
[TBL] [Abstract][Full Text] [Related]
35. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E
Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551
[TBL] [Abstract][Full Text] [Related]
36. Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification.
Kim M; Kim S; Park YW; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Chang JH; Kim SH; Lee SK
J Neurooncol; 2022 Sep; 159(3):695-703. PubMed ID: 35988090
[TBL] [Abstract][Full Text] [Related]
37. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
38. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
39. Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas.
Sahu A; Patnam NG; Goda JS; Epari S; Sahay A; Mathew R; Choudhari AK; Desai SM; Dasgupta A; Chatterjee A; Pratishad P; Shetty P; Moiyadi AA; Gupta T
J Pers Med; 2022 Dec; 13(1):. PubMed ID: 36675733
[TBL] [Abstract][Full Text] [Related]
40. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
